denosumab
Aliases
Prolia
3 clinical trials
4 products
12 abstracts
4 indications
Indication
Fibrous DysplasiaIndication
OsteoporosisIndication
PostmenopausalIndication
Osteoporotic fracturesClinical trial
A Phase 2 Study of Denosumab for Prevention of Skeletal Disease Progression in Children With Fibrous DysplasiaStatus: Recruiting, Estimated PCD: 2024-06-01
Abstract
A randomized, double-blind, study to evaluate the efficacy, pharmacodynamics, safety and immunogenicity of FKS518 proposed biosimilar to denosumab with the originator in postmenopausal women with osteoporosis (LUMIADE-3 study).Org: Center for Clinical and Basic Research AS,
Abstract
Real-world data of efficacy and safety of denosumab on patients with breast cancer with bone metastasis: Results from Chinese clinical experience.Org: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China,
Abstract
Incidence of osteonecrosis of the jaw (ONJ) in the randomized non-inferiority phase III trial SAKK 96/12 REDUSE comparing denosumab (DN) administered every 4 weeks (q4w) versus every 12 weeks (q12w).Org: Department of Medical Oncology, Kantonsspital Graubuenden, Chur, Switzerland, Med Onkologie, Winterthur, Switzerland, Kantonsspital Graubünden, Chur, Università della Svizzera Italiana, Lugano, Lugano, Switzerland, Cantonal Hospital St. Gallen, St. Gallen, Switzerland,
Abstract
A double-blind, randomized, two-arm, single-dose, parallel-group study in healthy participants to compare the pharmacokinetics, pharmacodynamics, and immunogenicity of FKS518 proposed biosimilar to denosumab with the originator (LUMIADE-1 study).Org: Lake Zurich, IL, MTZ Clinical Research Center, Eysins, Switzerland,
Clinical trial
Sustaining Skeletal Health in Frail ElderlyStatus: Completed, Estimated PCD: 2023-08-01
Clinical trial
Comparative Antiresorptive Efficacy of Alendronate or Raloxifene Following Discontinuation of DenosumabStatus: Active (not recruiting), Estimated PCD: 2023-02-01
Abstract
A phase 1B dose escalation study of ETC-159 in combination with pembrolizumab in advanced or metastatic solid tumours.Org: National University Cancer Institute, Singapore, Yong Loo Lin School of Medicine, National University of Singapore, National Cancer Centre Singapore, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, UCHealth Cancer Care-Anschutz Medical Campus-University of Colorado Cancer Center, Aurora, CO,
Abstract
Denosumab for smoldering multiple myeloma: Rates of osteoporosis and change in lowest T-score after 12 months of treatment.Org: University of Rochester Medical Center, Wilmot Cancer Institute, Rochester, NY,
Abstract
Oncologists’ receipt of pharmaceutical industry payments and use of non-recommended and low-value cancer care services.Org: Memorial Sloan Kettering Cancer Center, Vanderbilt University School of Medicine, DELFI Diagnostics, Medical College of Wisconsin,
Abstract
Pharmacokinetics and pharmacodynamics of proposed denosumab biosimilar and reference denosumab in healthy male subjects.Org: HEXAL AG, Parexel International GmbH,
Abstract
Bone health practices in metastatic prostate cancer (mPCA).Org: University of Colorado Cancer Center (UCCC), University of Colorado Cancer Center Biostatistics Core, University of Colorado School of Medicine,
Abstract
CHARLI: A phase Ib/II trial of ipilimumab-nivolumab-denosumab or nivolumab-denosumab in patients with unresectable stage III and IV melanoma.Org: Peter MacCallum Cancer Centre, Melbourne, Australia, Sir Charles Gairdner Hospital, Harry Perkins Institute for Medical Research, University of Western Australia & Linear Clinical Research, Melbourne, Australia,
Abstract
Denosumab biosimilar (LY01011) in the treatment of bone metastases in patients with solid tumors: A multicenter, randomized, double-blind, active comparator-controlled phase 3 study.Org: Fudan University Shanghai Cancer Center, Guangxi Tumor Hospital, Department of Medical Oncology, Harbin Medical University Cancer Hospital, First Affiliated Hospital of Gannan Medical University, Department of Oncology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China,
Abstract
Multicenter, retrospective population-based study on the incidence of medication-related osteonecrosis of the jaw in patients with breast cancer with bone metastases.Org: Department of Gynecology and Obstetrics, Medical University of Innsbruck, Innsbruck, Austria, Department of Obstetrics and Gynecology , Medical University of Innsbruck, Innsbruck, Austria, Department of Gynecology and Gynecological Oncology, Medical University of Innsbruck, Innsbruck, Austria, Department of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, Austria, Department of Cranio-Maxillofacial and Oral Surgery, Medical University of Innsbruck, Innsbruck, Austria,
Product
XGEVA®Product
Bone-targeted agentProduct
nivolumab, denosumab